Logo

ATRA

Atara Biotherapeutics, Inc.

ATRA

Atara Biotherapeutics, Inc. • NASDAQ
$15.10 ▲ 1.62% (+0.24)
Market Cap $108.86 M
52w High $18.70
52w Low $5.00
Dividend Yield 0%
P/E 5.28
Volume 17.98K
Outstanding Shares 7.21M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.453M ▼ $6.885M ▼ $-4.303M ▼ -124.616% ▼ $-0.32 ▼ $-3.33M ▼
Q2-2025 $17.575M ▼ $13.824M ▼ $2.387M ▼ 13.582% ▼ $0.2 ▼ $3.598M ▼
Q1-2025 $98.149M ▲ $38.908M ▲ $38.01M ▲ 38.727% ▲ $3.53 ▲ $40.822M ▲
Q4-2024 $32.753M ▼ $38.161M ▼ $-12.693M ▲ -38.754% ▲ $-1.19 ▲ $-10.595M ▲
Q3-2024 $40.19M $54.345M $-21.909M -54.514% $-2.93 $-19.513M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $13.712M ▼ $30.167M ▼ $66.801M ▼ $-36.634M ▼
Q2-2025 $22.323M ▲ $36.902M ▼ $71.943M ▼ $-35.041M ▲
Q1-2025 $13.841M ▼ $62.038M ▼ $117.11M ▼ $-55.072M ▲
Q4-2024 $42.496M ▼ $109.098M ▼ $206.381M ▼ $-97.283M ▼
Q3-2024 $67.189M $142.706M $233.245M $-90.539M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.303M ▼ $-9.787M ▼ $-2.421M ▲ $1.047M ▼ $-11.161M ▼ $-9.787M ▼
Q2-2025 $2.387M ▼ $-7.318M ▲ $-5.07M ▼ $15.304M ▲ $2.916M ▲ $-7.318M ▲
Q1-2025 $38.01M ▲ $-28.138M ▼ $17.199M ▲ $-250K ▲ $-11.189M ▲ $-28.138M ▼
Q4-2024 $-12.693M ▲ $-24.471M ▼ $3.376M ▲ $-328K ▼ $-21.423M ▼ $-24.561M ▼
Q3-2024 $-21.909M $-3.989M $-16.665M $35.793M $15.139M $-3.989M

Five-Year Company Overview

Income Statement

Income Statement Atara’s income statement looks like a classic high‑risk biotech profile: almost no product revenue yet, with the business still largely funded by investors rather than customers. Operating losses have been significant for years, driven by research, development, and overhead. The size of the losses has eased somewhat more recently compared with the deep trough a few years ago, but they remain substantial in relation to the tiny revenue base. Past net results also show one‑off hits that made some years look especially painful. Overall, the company has not yet demonstrated a self‑sustaining earnings model and remains very dependent on future milestones and approvals to change that picture.

Balance Sheet

Balance Sheet The balance sheet has weakened over time. Total assets, including cash, have steadily declined, showing that prior funding is being drawn down to cover ongoing losses. Cash is now much lower than in earlier years, and shareholder equity has flipped from positive to meaningfully negative, reflecting years of accumulated losses. Debt levels are not huge in absolute terms, but with a thin asset base and negative equity, even modest obligations matter more. The recent reverse stock split is a cosmetic move to maintain listing status, not a fix for the underlying capital shortfall. Overall, financial resilience is limited, and the company is heavily exposed to funding and partnership risk.

Cash Flow

Cash Flow Cash flow is consistently negative, with money flowing out of the business each year to pay for research, clinical work, and operations. The cash burn appears to have improved somewhat recently but is still clearly in the red. Free cash flow tells the same story: little to no spending on heavy equipment, but sizeable ongoing operating outflows. This means Atara is reliant on periodic capital raises, upfront payments, or milestones from partners to keep going. The internal engine does not yet generate cash; it consumes it, so the length of the cash runway and access to new funding are central issues.

Competitive Edge

Competitive Edge Atara holds a distinctive position as an early pioneer in off‑the‑shelf allogeneic T‑cell therapies, with a first‑in‑class approval in Europe for its lead product, Tab‑cel. Its proprietary Epstein‑Barr virus T‑cell platform, clinical experience, and partnership with Pierre Fabre provide real scientific and commercial credibility. However, the competitive landscape has tightened sharply, with multiple well‑funded rivals pursuing different allogeneic cell approaches. Manufacturing setbacks, regulatory delays in the U.S., and the discontinuation of several pipeline programs have eroded some of Atara’s practical advantage and left its story more concentrated around a single key product. The moat is now narrower and more execution‑dependent than it appeared a few years ago.

Innovation and R&D

Innovation and R&D Scientifically, Atara has built a genuinely innovative platform that uses donor‑derived EBV T‑cells to create off‑the‑shelf therapies, potentially avoiding some of the complexities and risks of gene‑edited approaches. The technology is versatile and has already delivered one approved medicine in Europe, which is a strong validation point. At the same time, the R&D narrative has become bumpier: a high‑profile multiple sclerosis program failed, leading to its shutdown, and CAR‑T programs have been discontinued after manufacturing and regulatory troubles. Recent restructuring suggests a sharper, more defensive focus on the core asset and platform rather than a broad pipeline. The key question for the future is whether Atara can convert its scientific foundation into a sustainable, replenished portfolio, likely through selective internal projects and deeper partnerships.

Summary

Atara today looks like a scientifically validated but financially strained biotech in a make‑or‑break phase. On the financial side, it has very small revenues, persistent losses, shrinking assets, negative equity, and ongoing cash burn, making access to capital and milestone payments crucial. On the strategic side, it owns a differentiated EBV T‑cell platform and a first‑in‑class approved therapy in Europe, but has suffered regulatory, manufacturing, and clinical setbacks that have thinned its pipeline and raised execution risk. The company is now heavily dependent on resolving manufacturing issues, securing and expanding U.S. approval for Tab‑cel, controlling costs, and potentially finding strategic partners or transactions. Outcomes around these few pivotal levers will likely have an outsized impact on the company’s long‑term viability and value, with considerable uncertainty in both directions.

NEWS

November 12, 2025 · 9:00 AM UTC

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Read more

November 3, 2025 · 9:00 AM UTC

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Read more